Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $30.2727.

BCAX has been the topic of a number of recent research reports. HC Wainwright upped their price target on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Wedbush restated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. Wells Fargo & Company upped their target price on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 31st. Finally, The Goldman Sachs Group increased their price target on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th.

Bicara Therapeutics Stock Performance

NASDAQ BCAX opened at $29.00 on Monday. The business’s fifty day moving average is $22.70 and its 200 day moving average is $19.71. Bicara Therapeutics has a fifty-two week low of $8.74 and a fifty-two week high of $29.90. The company has a market capitalization of $1.91 billion, a PE ratio of -10.43 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). On average, sell-side analysts forecast that Bicara Therapeutics will post -3.48 EPS for the current year.

Insider Buying and Selling

In related news, CFO Ivan Hyep sold 9,200 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $20.42, for a total transaction of $187,864.00. Following the sale, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,968,149.10. This represents a 5.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 15,000 shares of the stock in a transaction on Monday, April 20th. The shares were sold at an average price of $23.61, for a total value of $354,150.00. Following the sale, the chief executive officer owned 362,152 shares in the company, valued at $8,550,408.72. The trade was a 3.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,900 shares of company stock valued at $1,420,704 over the last quarter. Company insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BCAX. Cantor Fitzgerald L. P. purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $1,579,000. UBS Group AG raised its position in Bicara Therapeutics by 97.4% in the 4th quarter. UBS Group AG now owns 192,191 shares of the company’s stock worth $3,235,000 after purchasing an additional 94,829 shares during the period. Cinctive Capital Management LP purchased a new stake in Bicara Therapeutics in the 3rd quarter worth about $661,000. California State Teachers Retirement System lifted its stake in Bicara Therapeutics by 701.4% in the fourth quarter. California State Teachers Retirement System now owns 17,158 shares of the company’s stock worth $289,000 after purchasing an additional 15,017 shares during the last quarter. Finally, Algert Global LLC purchased a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $278,000.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.